BBIO – BridgeBio Pharma, Inc.
BBIO — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
14.14
Margin Of Safety %
Put/Call OI Ratio
0.96
EPS Next Q Diff
0.42
EPS Last/This Y
1.64
EPS This/Next Y
2.15
Price
71.99
Target Price
102.95
Analyst Recom
1.27
Performance Q
-2.03
Upside
-283.9%
Beta
1.16
Ticker: BBIO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | BBIO | 65.61 | 0.70 | 0.08 | 48659 |
| 2026-03-10 | BBIO | 74.35 | 0.70 | 0.34 | 48389 |
| 2026-03-11 | BBIO | 71.45 | 0.73 | 0.80 | 49476 |
| 2026-03-12 | BBIO | 68.03 | 0.73 | 0.07 | 51691 |
| 2026-03-13 | BBIO | 67.98 | 0.73 | 0.07 | 51691 |
| 2026-03-17 | BBIO | 71.02 | 0.70 | 0.01 | 53391 |
| 2026-03-18 | BBIO | 70.09 | 0.69 | 0.10 | 53519 |
| 2026-03-19 | BBIO | 70.14 | 0.68 | 0.87 | 54011 |
| 2026-03-20 | BBIO | 68.26 | 0.69 | 3.28 | 54417 |
| 2026-03-23 | BBIO | 69.62 | 0.80 | 1.09 | 37377 |
| 2026-03-24 | BBIO | 68.57 | 0.81 | 4.44 | 38574 |
| 2026-03-25 | BBIO | 71.62 | 0.85 | 0.12 | 39459 |
| 2026-03-26 | BBIO | 72.3 | 0.84 | 0.01 | 39674 |
| 2026-03-27 | BBIO | 69.72 | 0.79 | 0.01 | 41180 |
| 2026-03-30 | BBIO | 69.37 | 0.80 | 0.06 | 40734 |
| 2026-03-31 | BBIO | 74.02 | 0.78 | 0.11 | 41301 |
| 2026-04-01 | BBIO | 74.44 | 0.78 | 19.24 | 41616 |
| 2026-04-02 | BBIO | 73.19 | 1.00 | 0.04 | 46912 |
| 2026-04-06 | BBIO | 72.31 | 0.96 | 0.12 | 47968 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | BBIO | 65.61 | 49.4 | 260.2 | -1.76 |
| 2026-03-10 | BBIO | 74.38 | 43.9 | 225.6 | -1.78 |
| 2026-03-11 | BBIO | 71.32 | 43.9 | 272.1 | -1.78 |
| 2026-03-12 | BBIO | 67.99 | 34.3 | 274.0 | -1.78 |
| 2026-03-13 | BBIO | 69.36 | 34.3 | 281.5 | -1.96 |
| 2026-03-17 | BBIO | 70.94 | 34.3 | 286.5 | -1.96 |
| 2026-03-18 | BBIO | 70.08 | 34.3 | 285.0 | -1.96 |
| 2026-03-19 | BBIO | 70.14 | 34.3 | 164.2 | -1.96 |
| 2026-03-20 | BBIO | 68.54 | 34.3 | 171.9 | -1.96 |
| 2026-03-23 | BBIO | 69.63 | 32.5 | 158.8 | -2.14 |
| 2026-03-24 | BBIO | 68.54 | 32.5 | 169.7 | -2.14 |
| 2026-03-25 | BBIO | 71.61 | 32.5 | 148.3 | -2.14 |
| 2026-03-26 | BBIO | 72.61 | 32.5 | 159.3 | -2.14 |
| 2026-03-27 | BBIO | 69.72 | 32.5 | 178.4 | -2.14 |
| 2026-03-30 | BBIO | 69.36 | 32.5 | 166.0 | -2.14 |
| 2026-03-31 | BBIO | 74.29 | 32.5 | 139.1 | -2.14 |
| 2026-04-01 | BBIO | 74.39 | 32.5 | 163.7 | -2.14 |
| 2026-04-02 | BBIO | 73.12 | 32.5 | 170.7 | -2.14 |
| 2026-04-06 | BBIO | 72.29 | 32.5 | 168.5 | -2.14 |
| 2026-04-07 | BBIO | 71.99 | 32.5 | 165.8 | -2.14 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | BBIO | -3.53 | 1.57 | 12.73 |
| 2026-03-10 | BBIO | -3.53 | 1.57 | 12.73 |
| 2026-03-11 | BBIO | -3.53 | 1.57 | 13.21 |
| 2026-03-12 | BBIO | -3.56 | 1.57 | 13.21 |
| 2026-03-13 | BBIO | -3.56 | 1.57 | 13.21 |
| 2026-03-17 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-18 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-19 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-20 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-23 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-24 | BBIO | -3.83 | 1.62 | 13.21 |
| 2026-03-25 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-03-26 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-03-27 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-03-30 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-03-31 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-04-01 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-04-02 | BBIO | -3.83 | 1.62 | 14.14 |
| 2026-04-06 | BBIO | -3.83 | 1.63 | 14.14 |
| 2026-04-07 | BBIO | -3.83 | 1.63 | 14.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.94
Avg. EPS Est. Current Quarter
-0.67
Avg. EPS Est. Next Quarter
-0.52
Insider Transactions
-3.83
Institutional Transactions
1.63
Beta
1.16
Average Sales Estimate Current Quarter
177
Average Sales Estimate Next Quarter
210
Fair Value
Quality Score
73
Growth Score
55
Sentiment Score
72
Actual DrawDown %
15.3
Max Drawdown 5-Year %
-91.9
Target Price
102.95
P/E
Forward P/E
101.93
PEG
P/S
27.77
P/B
P/Free Cash Flow
EPS
-3.78
Average EPS Est. Cur. Y
-2.14
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-144.39
Relative Volume
0.41
Return on Equity vs Sector %
7.3
Return on Equity vs Industry %
23.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.38
EBIT Estimation
165.8
◆
BBIO
Healthcare
$71.93
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
52.3
Range 1M
63.8%
Sup Dist
0.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
48.3%
EPS NY
136.1%
52W%
76.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+43.1% upside
Upside
+43.1%
Quality
73
BridgeBio Pharma, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 834
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BBIO
Latest News
—
Caricamento notizie per BBIO…
stock quote shares BBIO – BridgeBio Pharma, Inc. Stock Price stock today
news today BBIO – BridgeBio Pharma, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BBIO – BridgeBio Pharma, Inc. yahoo finance google finance
stock history BBIO – BridgeBio Pharma, Inc. invest stock market
stock prices BBIO premarket after hours
ticker BBIO fair value insiders trading